Vertex Pharmaceuticals Inc. (VRTX)
Wall Street Analysts See Vertex (VRTX) as a Buy: Should You Invest?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Is Trending Stock Vertex Pharmaceuticals Incorporated (VRTX) a Buy Now?
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex Pharmaceuticals (VRTX) Stock Declines While Market Improves: Some Information for Investors
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $460, moving -1.06% from the previous trading session.
The Best Biotech Stock to Invest $1,000 in Right Now
Vertex Pharmaceuticals is unusually resilient for a biotech stock. The company has spectacular growth prospects with multiple promising late-stage programs.
Vertex Pharmaceuticals Incorporated (VRTX) Management presents at Cantor Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Cantor Global Healthcare Conference September 17, 2024 9:10 AM ET Company Participants Susie Lisa - SVP, IR Manisha Pai - Executive Director, IR Conference Call Participants Olivia Brayer - Cantor Fitzgerald Olivia Brayer Joining us this morning at our Cantor Global Healthcare Conference. Really excited to have another year of it.
Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know
Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.
Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?
Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vertex Pharmaceuticals, Inc. (VRTX) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX ) Morgan Stanley Conference Call September 5, 2024 11:30 AM ET Company Participants Reshma Kewalramani - President and CEO Charlie Wagner - CFO Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn Thanks for joining us, everybody. I'm Terence Flynn, the U.S. biopharma analyst here at Morgan Stanley.
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.
Forget Novo Nordisk: Buy This Magnificent Pharma Stock Instead
Vertex Pharmaceuticals is different from Novo Nordisk in several ways. The two companies could compete against each other in the future.
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why
Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.
